Skip to main
AMGN

Amgen (AMGN) Stock Forecast & Price Target

Amgen (AMGN) Analyst Ratings

Based on 12 analyst ratings
Hold
Strong Buy 8%
Buy 25%
Hold 58%
Sell 8%
Strong Sell 0%

Bulls say

Amgen has demonstrated impressive sales growth, with a 40% increase in the third quarter of 2025 compared to the same period in 2024, driven by multiple products showing double-digit growth, including significant performance from Repatha and Tezspire. The company has raised its fiscal year 2025 revenue guidance to a range of $35.8 billion to $36.6 billion, reflecting continued strength across its established therapeutic franchises and a robust pipeline bolstered by recent acquisitions. Additionally, Amgen is prioritizing research and development with a planned growth rate of over 20% in 2025, indicating a commitment to innovation and future revenue generation in the biotechnology sector.

Bears say

Amgen's financial outlook is negatively impacted by projected revenue growth of only approximately 1% in 2026, which is exacerbated by expected annual sales declines of around 28% for Prolia and 39% for Xgeva. Additionally, management indicated that growth in research and development spending will be more restrained relative to 2025, which could limit future innovation and competitiveness. Overall, despite Amgen's strong existing product portfolio and cash flows, the impending loss of exclusivity for key drugs and uncertain prospects for emerging products raise concerns about sustainable long-term growth.

Amgen (AMGN) has been analyzed by 12 analysts, with a consensus rating of Hold. 8% of analysts recommend a Strong Buy, 25% recommend Buy, 58% suggest Holding, 8% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Amgen and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Amgen (AMGN) Forecast

Analysts have given Amgen (AMGN) a Hold based on their latest research and market trends.

According to 12 analysts, Amgen (AMGN) has a Hold consensus rating as of Jan 9, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $322.17, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $322.17, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Amgen (AMGN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.